|
| Press Releases |
|
 |
|
| Monday, April 27, 2020 |
|
|
Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine |
| This selection is based on Eisai's being ranked first place in "Best CEOs" and "Best CFOs", respectively, in the sector. more info >> |
|
| Thursday, April 2, 2020 |
|
|
エーザイと生化学工業、変形性関節症治療剤SI-613について中国における共同開発及び販売提携に関する契約を締結 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）と生化学工業株式会社（本社：東京都、代表取締役社長：水谷建、以下 生化学工業）は、このたび、生化学工業が創出した変形性関節症治療剤 SI-613（ジクロフェナク結合ヒアルロン酸）について、中国における共同開発及び販売提携に関する契約を締結しましたのでお知らせします。 more info >> |
|
| Wednesday, April 1, 2020 |
|
|
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China |
| Eisai Co., Ltd. and Seikagaku announced today that the companies have entered into an agreement for the co-development and marketing alliance in China for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku. more info >> |
|
| Thursday, March 26, 2020 |
|
|
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant) |
| Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL). more info >> |
|
|
エーザイ、抗がん剤「デニロイキン ジフチトクス（遺伝子組換え）」の日本における皮膚T細胞性リンパ腫および末梢性T細胞リンパ腫に係る適応で新薬承認申請書を提出 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、日本において、抗がん剤デニロイキン ジフチトクス（遺伝子組換え）（一般名、開発コード：E7777）について、皮膚 T 細胞性リンパ腫（Cutaneous T-Cell Lymphoma : CTCL）および末梢性 T 細胞リンパ腫（Peripheral T-Cell Lymphoma : PTCL）に係る適応の新薬承認申請書を提出したことをお知らせします。 more info >> |
|
| Wednesday, March 25, 2020 |
|
|
エーザイ、マルチキナーゼ阻害剤レンバチニブの創製「2020年度 日本薬学会創薬科学賞」を受賞 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、当社が創製した経口マルチ キナーゼ阻害剤レンバチニブメシル酸塩（製品名：「レンビマ(R)」、以下 レンバチニブ）の創薬研究が、日本薬学会より「2020年度 日本薬学会創薬科学賞」を受賞したことをお知らせします。 more info >> |
|
|
Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20 |
| Eisai Co., Ltd. has announced that drug discovery research conducted on lenvatinib mesylate (brand name: LENVIMA, lenvatinib), the orally available multikinase inhibitor discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development '20 by the PSJ. more info >> |
|
| Monday, March 23, 2020 |
|
|
エーザイ、ブレインパフォーマンス（脳の健康度）を定期的にセルフチェックするためのデジタルツール「のうKNOW(TM)」を日本において新発売 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、Cogstate Ltd.（本社：オーストラリア 以下 Cogstate 社）が創出した認知機能テスト「Cogstate Brief Battery(TM)」(以下 CBB)について、日本において、ブレインパフォーマンス（脳の健康度）をセルフチェックするためのデジタルツール（非医療機器）として開発し、「のう KNOW(TM)」（読み：ノウノウ）の製品名で 3 月 31 日に新発売することをお知らせします。自治体や企業等の法人向けから販売を開始します。 more info >> |
|
|
Eisai to Launch Digital Tool "NouknowTM" in Japan for Regular Self-Assessment of Brain Performance (Brain Health) |
| Eisai Co., Ltd. announced today that it will launch "NouKNOWTM", a new digital tool (non-medical device) for self-assessment of brain performance (brain health). more info >> |
|
| Thursday, March 19, 2020 |
|
|
Eisai: All-case Surveillance Condition for Approval of "Actonel 17.5 mg tablets" for Treatment of Paget's Disease of Bone Cleared in Japan |
| EA Pharma Co., Ltd. and Eisai Co., Ltd. continually strive to promote proper use of the product and provide timely additional information of the product to increase benefits to patients and their families. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Lit Studios enters into MOU with Bingo Group, a Hong Kong listed company
Mar 14, 2025 20:45 HKT/SGT
|
|
|
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
Mar 14, 2025 19:54 HKT/SGT
|
|
|
Approval in Principle (AiP) for the Basic Design of a Large Ammonia-Fueled Ammonia Carrier Obtained from Classification Society
Mar 14, 2025 18:37 JST
|
|
|
Toyota Launches All-New Crown Estate in Japan
Mar 14, 2025 17:22 JST
|
|
|
Probowangi Toll Road Package 3 Reaches 74.9% Completion, WIKA Supports Logistics Efficiency and National Connectivity
Mar 14, 2025 16:00 HKT/SGT
|
|
|
三菱造船、アンモニアを燃料とする大型アンモニア輸送船の設計基本承認（AiP）を船級協会から取得
Mar 14, 2025 14:15: JST
|
|
|
富士通、「第57回（令和６年度）市村賞 市村産業賞」の「貢献賞」を受賞
Mar 14, 2025 12:50: JST
|
|
|
Habitat for Humanity offers up to US$40,000 in grants for innovative youth-led housing solutions in Asia-Pacific
Mar 14, 2025 10:18: JST
|
|
|
Habitat for Humanity offers up to US$40,000 in grants for innovative youth-led housing solutions in Asia-Pacific
Mar 14, 2025 09:18 HKT/SGT
|
|
|
TreasureNFT Introduces New Features to Enhance NFT Trading Efficiency
Mar 14, 2025 09:00: JST
|
|
|
TreasureNFT Introduces New Features to Enhance NFT Trading Efficiency
Mar 14, 2025 08:00 HKT/SGT
|
|
|
Future of airport operations to take centre stage at inter airport Southeast Asia conference
Mar 14, 2025 07:58 HKT/SGT
|
|
|
CleverTap partners with upGrad to build a Deep Learning Track to upskill Marketers with Hands-On AI & Analytics Training
Mar 14, 2025 04:00 HKT/SGT
|
|
|
Hong Kong delegation concludes IRES mission in Bangkok
Mar 13, 2025 16:41: JST
|
|
|
CleverTap partners with upGrad to build a Deep Learning Track to upskill Marketers with Hands-On AI & Analytics Training
Mar 13, 2025 16:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
